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women (4). Although in vivo evaluation of blood rheology is
difficult, in vitro data suggest that optimal oxygen delivery (bal-
ancing oxygen delivery and blood viscosity) occurs at hematocrit
levels between 38% to 51% (9).
Importantly, different therapies addressing the same target may
be associated with a different balance of risks and benefits, and
therapies may exert therapeutic or harmful effects through path-
ways unrelated to their presumed mechanisms. As Dr. Kovacic
points out and as we stated in our review, emerging data suggest a
role for erythropoietin in cardioprotection from ischemic injury.
Such data raises the possibility that erythropoietin analogs may
have beneficial effects in cardiovascular disease that are distinct
from their effects on erythrogenesis. Conversely, recently published
data suggest that red blood cell transfusions are associated with an
increase of ischemic events in patients with acute coronary syn-
dromes, possibly due to lack of ability of stored erythrocytes to
effectively donate nitric oxide in the microvasculature (10). Given
the uncertain balance of risks and benefits of therapy with
erythropoietin analogs in patients with heart failure, the clinical
equipoise required to proceed with carefully controlled, appropri-
ately powered randomized trials clearly exists. As we stated in our
conclusions, we continue to believe “a mixture of optimism and
caution” is the appropriate stance until results from such trials are
available.
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Conflation of Empiric and Nonempiric
Truths in Cardiovascular Guidelines
The newly published guidelines for the treatment of ST-elevation
myocardial infarction (STEMI) use the more detailed definitions
of classes of recommendations and levels of evidence as shown in
Table 1 of the report (1). Unfortunately, this system continues to
conflate empiric and nonempiric information, despite the fact that
these issues are incommensurable and should not be reflected
within a single evidentiary hierarchy system. The result of this
commingling is that nonempiric facts are erroneously assigned to
the lowest level of certainty. These assignments reflect confusion
between those instances where evidence is subject to, but has yet to
be, scientifically tested, and those instances wherein the truth of
the statement cannot be empirically proven. For example, the Class
I recommendation regarding the need for an electrocardiogram
(ECG) is considered a matter of expert consensus, and though this
is true, the consensus does not pertain to an experimentally based
question but rather to the current definition of the disease state
being discussed. The ECG is the sine qua non of STEMI. All
experimentation presupposes this definition. Until the definition is
amended or the measurement tool changed, the certainty that an
ECG is needed is absolute. This is a nonempiric statement that
does not need to be, nor can it be, experimentally proven. Its
certainty is parallel to, not subordinate to, the best experimental
data.
Similarly, the Class III recommendation not to do coronary
angiography on patients where the risks of revascularization
outweigh the benefits reflects the nonempiric moral dictum to do
no harm. This is a concept that is not open to experimental proof,
but is an absolute that forms the basic fabric of our profession.
Many other examples of undervalued nonempiric statements
appear throughout cardiovascular guidelines. Future task forces/
writing groups need to recognize that nonempiric concepts should
be separated from empiric concepts and that nonempiric data
represent levels of certainty that are parallel to, not subordinate to,
empiric data.
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